ALXN - Alexion Pharmaceuticals, Inc.
| Previous Close | 109.50 |
| Open | 109.60 |
| Bid | 111.61 x 900 |
| Ask | 111.68 x 900 |
| Day's Range | 109.15 - 112.27 |
| 52 Week Range | 92.56 - 141.86 |
| Volume | 1097799 |
| Avg. Volume | 1,792,806 |
| Market Cap | 25B |
| Beta (3Y Monthly) | 1.67 |
| PE Ratio (TTM) | 17.19 |
| EPS (TTM) | 6.52 |
| Earnings Date | Feb 3, 2020 - Feb 7, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 149.45 |
- Zacks
6 Low Price-to-Book Value Stocks to Buy in December
P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.
- Kiplinger
The 13 Best Health-Care Stocks to Buy for 2020
One of the most attractive reasons to invest in health-care stocks continues to be the world's aging population.The United Nations says people age 65 and older are the fastest-growing age group worldwide. It estimates that by 2050, one out of every six people will be 65 or older, accounting for 16% of the planet's total population, up from 9% in 2011. That figure is even larger in Europe and North America, where the U.N. predicts the number will be closer to 25%. The demand for health-care products and services should only increase as a result.Yes, health-care stocks will be coming off a weak 2019. Through mid-November, the S&P; 500 was sitting on nearly 25% gains, while the sector had improved by roughly half that. They'll also have to contend with uncertainty regarding the future of health care as the 2020 presidential election approaches. But don't sleep on the space in the year ahead.For one, health-care stocks tend to outperform during periods of economic weakness. For instance, the Health Care Select Sector SPDR Fund (XLV) delivered a 39.6% total loss (share price plus dividends) during the 2007-09 bear market - more than 15 percentage points better than the S&P; 500\. Thus, headlines warning of an economic slowdown or even a recession in 2020 actually bode well for the sector.Also, health care has traded at a price-to-earnings ratio more expensive than the overall market more often than not over the past 20 years. However, according to the Charles Schwab Center for Research, the sector's P/E currently is cheaper than the S&P; 500, providing a better buying opportunity.Here, then, are the 13 best health-care stocks to buy for 2020, including a couple of funds for investors who want to diversify. SEE ALSO: Every Warren Buffett Stock Ranked: The Berkshire Hathaway Portfolio
- Zacks
Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com
Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com
- Zacks
Alexion (ALXN) Looks Good: Stock Adds 6% in Session
Alexion (ALXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Zacks
Create a Standout Portfolio With These 4 Low P/CF Stocks
Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.
- Investor's Business Daily
An Activist Investor Pushed This Biotech To Sell — Why It Refused
Alexion Pharmaceuticals decided against selling itself, the biotech company said in a news release on Friday — prodding ALXN stock to jump. An activist investor suggested it launch a sale.
- Barrons.com
The Dow Is Up 336 Points Because the Jobs Report Was Just That Good
The Dow Jones Industrial Average gained 1.2% on a strong November employment report, while the S&P 500 and the Nasdaq Composite were both trading up 1.0%.
- Bloomberg
Alexion Rejects Elliott Affiliate’s Push to Put Biotech on Block
(Bloomberg) -- Alexion Pharmaceuticals Inc. said that putting itself up for sale wouldn’t be in the best interest of its shareholders, rejecting a proposal by an activist investor.The biotechnology company said in a statement on Friday that Elliott Advisors, an affiliate of investment firm Elliott Management Corp., had recommended that it launch a sales process but that its board determined that such a move wasn’t advisable.“Our Board considered, among other factors, that it is highly unusual, if not unprecedented, for a biopharmaceutical company of our size and maturity to proactively launch a sale process,” the company said in its statement. “We do not believe this approach is the best path for driving shareholder value.”Alexion said no buyers had come forward to express an interest and that it hadn’t rejected any offers.Shares of the drugmaker were up 2.9% at $110.58 at 10:04 a.m. on Friday. Since the start of the year, the stock has risen more than 13%, though those gains trail a 23% advance in the Nasdaq Biotechnology Index.A representative for Elliott didn’t immediately respond to a request for comment.Elliott, which is run by billionaire Paul Singer, hasn’t officially disclosed a stake in Alexion, although it had previously pushed for changes at the company. The New York-based hedge fund built a position in the drugmaker in 2017 and was pushing for board changes and a possible sale of the company, people familiar with the matter said at the time.Elliott and Alexion reached an agreement in early 2018 to jointly identify a new member for the board.Deborah Dunsire was subsequently added as a director. Alexion said in its release on Friday that the board unanimously decided that conducting a proactive sale process wouldn’t be in the best interest of shareholders.To contact the reporters on this story: Scott Deveau in New York at sdeveau2@bloomberg.net;Timothy Annett in New York at tannett@bloomberg.netTo contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- MarketWatch
Alexion stocks rises on decision not to consider a sale
Shares of Alexion Pharmaceuticals are up 6% in morning trading after the company halted its stock in premarket trading to announce that it would not consider a sale, as recommended by Elliott Management. The biopharmaceutical company said its board had unanimously decided not to pursue a sale and that it had not received any offers. "We do not believe this approach is the best path for driving shareholder value," the company said in a statement. Alexion markets several drugs, including Soliris, a treatment for a number of rare diseases that costs $500,000 a year. Shares of Alexion have gained 10% year-to-date, compared to the S&P 500 , which is up 24%.
- Zacks
Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo
Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo
- Reuters
UPDATE 3-Alexion Pharma rejects Elliott's push for "proactive sale"
Alexion Pharmaceuticals Inc said on Friday its board of directors had unanimously rejected hedge fund Elliott Management's push for a "proactive sale" process of the entire company because it would not be in the best interest of shareholders. Alexion has been fighting to maintain its leadership in treating certain rare blood disorders, and has embarked on a string of acquisitions to boost its pipeline of rare disease drugs. In October, it agreed to buy rival Achillion Pharmaceuticals Inc for about $930 million.
- Business Wire
Alexion Issues Statement on Path to Value Creation
Alexion Issues Statement on Path to Value Creation
- Barrons.com
The Dow Goes Negative Despite a Glimmer of Hope on Trade
STOCKSTOWATCHTODAY BLOG Reversal. The three major U.S. stock mark indexes slipped into negative territory after beginning the day in the green amid continued optimism about trade. Near midday, the Dow Jones Industrial Average was down 33 points, or 0.
- Zacks
5 Discounted PEG Stocks for GARP Investors
Although PEG is categorized under value investing, it follows the principles of both growth and value investing.
- Zacks
Adopt Rising P/E Technique With These 5 Top-Ranked Stocks
What bargain hunting? Stocks with a rising P/E can also be worth buying too.
- Zacks
ALXN vs. ILMN: Which Stock Is the Better Value Option?
ALXN vs. ILMN: Which Stock Is the Better Value Option?
- Insider Monkey
Hedge Funds Are Getting Crazy About Alexion Pharmaceuticals, Inc. (ALXN)
Is Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]
- Zacks
Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More
Key highlights of the past week include regulatory and pipeline updates.
- Zacks
The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion
The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion
- Business Wire
Alexion to Present at the 2019 Evercore ISI HealthCONx
Alexion Pharmaceuticals today announced that management will present at the 2019 Evercore ISI HealthCONx in Boston, MA on Tuesday, December 3rd, 2019 at 8:45 a.m. ET.
- Zacks
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal
Here are four stocks that boast promising prospects and are most likely to be takeout targets.
- TipRanks
Billionaire Ray Dalio Snaps Up These 3 “Strong Buy” Stocks
When billionaire financier Ray Dalio makes a move, Wall Street pays attention. Dalio, who got his start working on the floor of the New York Stock Exchange trading commodity futures, founded the world’s largest hedge fund, Bridgewater Associates, in 1975. With the firm managing about $150 billion in global investments and Dalio’s own net worth coming at $18.7 billion, he has earned guru-like status by taking the opinions of experts that disagreed with him into consideration.“I learned a great fear of being wrong that shifted my mind-set from thinking ‘I’m right’ to asking myself ‘How do I know I’m right?’ And I saw clearly that the best way to answer this question is by finding other independent thinkers who are on the same mission as me and who see things differently from me,” he wrote in his book Principles.On Friday, the Wall Street Journal reported that Bridgewater made a more than $1 billion bet that the market would drop in the next few months. However, Dalio took to Twitter to deny this, claiming that the firm has no such bet. Against this backdrop, investors want to know if the fund manager is simply hedging the portfolio, or if the firm is really as bearish as the report made it out to be.Looking into Bridgewater's basket of stocks, we’ve chosen three of the fund’s new holdings that TipRanks’ Stock Screener reveals as "strong buys" and offer healthy upside potential. Let's take a closer look and see what Wall Street analysts have to say.Cleveland-Cliffs (CLF)Formerly known as Cliffs Natural Resources, Cleveland-Cliffs is one of the top iron ore mining companies and operators. Not only is it the largest iron ore producer of pellets in North America but the steel company also takes its place as one of the lowest cost producers in the world.During the third quarter, Bridgewater upped the ante by 110%, adding 2,134,146 shares of the company to the fund. This brings Bridgewater’s total CLF holding to 4,081,690 shares, valued at $29.5 million.Recently, steel prices have been facing significant pressure. Tariffs as well as the high cost of raw-materials have led to price increases, while weakening U.S. industrial production has in turn caused demand for steel to drop. Nonetheless, the bulls are standing firmly behind CLF.B.Riley FBR analyst Lucas Pipes sees its briquetted iron (HBI) growth project, which should reach production in the first half of 2020, as well as its level of diversification as giving it a leg up. “We believe that Cliffs retains considerable upside in a stronger commodity price environment in addition to the diversification and strategic benefits of the HBI project,” he commented. As a result, the analyst kept his Buy rating but did adjust his price target from $13 to $12. This implies that there’s room for 51% upside potential. (To watch Pipes’ track record, click here)Like Pipes, Credit Suisse analyst Curt Woodworth reduced the price target from $12 to $10 following CLF’s third quarter earnings results while remaining bullish overall. Even though he acknowledges that “the move lower in pellet premiums and HRC as well as mix shifts (less export) have conspired to lower the ASP outlook for CLF”, he believes that demand for HBI could be a major profit driver. He adds, “We believe the Street is too negative on CLF given optionality to benefit from new EAF production…CLF remains a best-in-class mining asset with significant FCF potential over the cycle.” (To watch Woodworth’s track record, click here)In general, the rest of the Street is in agreement. 6 Buys and 2 Holds assigned in the last three months add up to a ‘Strong Buy’ consensus. In addition, its $9.66 average price target suggests 21% upside potential. (See Cleveland-Cliffs stock analysis on TipRanks)Alexion Pharmaceuticals (ALXN) Alexion is a biopharma company trying to improve the lives of patients with rare disease including paroxysmal nocturnal hemoglobinuria (PNH), generalized Myasthenia Gravis (gMG), atypical hemolytic uremic syndrome (aHUS) as well as several others.Despite its impressive performance in its most recent quarter in terms of its financial results and solid execution commercially, shares have been weighed down by concerns over its C5 inhibitor franchise. Alexion is gearing up to face competition from biosimilar products currently in Phase 3 development. On top of this, Roche’s Japanese subsidiary, Chugai Pharmaceutical, filed a patent infringement suit against Alexion.To this end, the Street is keeping a close watch on ALXN following Dalio’s purchase. The billionaire’s fund snapped up 445,246 shares during the third quarter, bringing Bridgewater’s total ALXN stake to 475,487 shares, up a whopping 1473% from the previous quarter.Piper Jaffray analyst Christopher Raymond reminds investors that there are still big potential gains in store for ALXN in 2020. “As impressive commercial performance and pipeline development have continued, and with what we view as an increasingly credible defensive strategy to protect against biosimilar competition, we continue to like the setup on this name,” he explained. This prompted the five-star analyst to keep an Overweight rating and $180 price target. At this target, shares could climb 62% higher over the next twelve months. (To watch Raymond’s track record, click here)Similarly, other analysts have high hopes for the biopharma. With 18 Buys and 2 Holds given over the last three months, the consensus is that ALXN is a ‘Strong Buy’. Not to mention there’s 35% upside potential based on the $151 average price target. (See Alexion stock analysis on TipRanks)EQT Corporation (EQT)EQT is the largest natural gas producer in the U.S. with its asset base located in the heart of the Appalachian Basin. With shares down 52% year-to-date, investors are watching this name following Dalio’s decision to increase the fund’s holding.Dalio just added an additional 1,177,026 shares to the fund, bumping up the stake by 88% from the previous quarter. The holding’s value is now at $26.9 million, based on its total stake of 2,529,370 shares.It should be noted that several of the Street’s analysts highlight the fact the EQT is taking steps in the right direction. The management team has been using technology in order to improve its logistic and operational processes. RBC Capital analyst Scott Hanold argues this should “enable EQT to reduce well costs toward $730/lateral foot from the historical $970/foot.”On top of this, the company is potentially selling its Equitrans Midstream ownership within the next nine months, lending itself to Hanold’s conclusion that there will be a $0.10-0.15/Mcfe reduction for EQT. The analyst adds, “EQT shares are currently trading at just 4.4x our 2020 EBITDA, a slight discount to peers, despite having an FCF yield that could reach 10+%. We acknowledge the risk of a few bumps in the road with the new strategies, but the new team appears positioned to execute at EQT’s scale.”To this end, the analyst boosted the rating to Outperform and increased the price target from $16 to $17. This conveys his confidence in EQT’s ability to soar 88% over the next twelve months. (To watch Hanold’s track record, click here)Most analysts back Hanold's confident take on the gas giant, as TipRanks analytics showcase EQT as a Strong Buy. Based on 4 analysts polled by TipRanks in the last 3 months, 3 rate a Buy on the stock stock while one says "hold." The 12-month average price target stands at $14.00, marking a nearly 60% upside from where the stock is currently trading. (See EQT stock analysis on TipRanks)
- Zacks
Alexion Gets Approval for Label Expansion of Soliris in Japan
Alexion (ALXN) gets Japan Ministry of Health, Labour and Welfare's approval for the label expansion of Soliris.
